A century after the nuanced connection between cancer and the immune system was discovered, researchers are working to arm the body’s immune system against cancer. The 2011 approval of a therapeutic antibody in melanoma, one of the most immunogenic types of cancer, validated this approach, and the next generation of immunotherapies is moving through the pipeline, with several companies racing to develop checkpoint inhibitors, adoptive T-cell therapies and other treatments that harness the body’s own defenses. One of these new agents received the FDA’s ‘Breakthrough Designation,’ and there is hope that these therapies could be paired with existing treatment options for improved outcomes. What makes this new class of immunotherapies different and how do they stack up against existing options? This session will discuss how these new agents could change the treatment paradigm for cancer and improve patient outcomes, and will identify drug development challenges yet to be overcome in the space.
- Examine the modalities of the new class of immunotherapies
- Focus on melanoma as a case study for immunotherapy that has yielded insights to help fight other cancer types
- Present insight into the opportunities and challenges of developing combinatorial immunoagents to treat cancer
Ability Level: Advanced
Session ID: 2467